StockData
Tenaya Therapeutics, Inc. logo

Tenaya Therapeutics, Inc. (TNYA) company profile

TNYANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$0.32−0.01 (-3.24%)

Close on Nov 17, 2026Market cap $72.38MP/E –Yield –

About Tenaya Therapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company that discovers and develops therapies targeting the underlying drivers of heart disease. Its lead product candidates include TN-201, an adeno-associated virus gene therapy in clinical trials for hypertrophic cardiomyopathy associated with MYBPC3 genetic variants, and TN-401, a gene therapy in clinical trials for arrhythmogenic right ventricular cardiomyopathy associated with PKP2 variants. The company also develops TN-301, a small molecule histone deacetylase 6 inhibitor investigated for heart failure with preserved ejection fraction and other disorders. Its target patient populations comprise individuals affected by rare genetic and prevalent cardiovascular conditions, and it collaborates with pharmaceutical partners.

The company conducts its activities in the United States, with facilities that include office and laboratory space in South San Francisco, California, as well as a manufacturing facility in Union City, California. Tenaya Therapeutics is headquartered in South San Francisco, California.

Summary of the business section of Tenaya Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Tenaya Therapeutics, Inc.
Headquarters
South San Francisco, CA
Address
171 Oyster Point Blvd., Suite 500 94080
Phone
(415) 865-2066
Employees
70, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, San Francisco, California

Stock & identifiers

Ticker
TNYA
Exchange
Nasdaq
IPO date
Jul 30, 2021
Shares outstanding
224M, Jul 30, 2026
Public float
$63.10M, Jun 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
1858848
CUSIP
87990A106
ISIN
US87990A1060
FIGI
BBG00FPMK2S3
Share class FIGI
BBG00FPMK2T2
EIN
81-3789973

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Faraz AliChief Executive Officer, Director539,782
Whittemore TingleyChief Medical Officer263,073
Eric J. HyllengrenChief Financial Officer–
Tomohiro HigaSVP, Finance118,267
Karah Herdman ParschauerDirector–
R. Sanders WilliamsDirector29,999
Catherine Stehman-BreenDirector8,125
June LeeDirector–
Jeffrey T. WalshDirector–
Deepak SrivastavaDirector564,101
Amy L. BurroughsDirector–
David V. GoeddelDirector49,313,559

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Faraz Ali
Chief Executive Officer
$664.17K$141.92K$755.51K$319.28K$516$1.88M-43%
Whittemore (Whit) Tingley
Chief Medical Officer
$521.19K$86.73K$385.07K$180.14K$1.52K$1.17M-29%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 30, 2021
Offer price
$15.00
Securities offered
12,000,000
Gross proceeds
$180.00M
Exchange
Nasdaq
First trading day
Jul 30, 2021
First-day close
$15.35+2.3%
Lock-up ends (est.)
Jan 26, 2022

“The initial public offering price is $15.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 70 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?